United States & Eli Lilly and Company
48 shared events · Importance 8 · Last updated Aug 15, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: Key market for obesity drugs; pricing pressure and competition are central to the rivalry.
Eli Lilly and Company: Main rival; maintains lead with Tirzepatide and Tirzepatide, but faces lawsuit and competition from oral Semaglutide.
Aug 03, 2026 · 6 articles
Domestic
United States: The United States is involved in a fragile truce with Iran and its economy is showing slower-than-expected growth and elevated consumer prices, leading to potential interest rate hikes by the United States — Federal Reserve.
Eli Lilly and Company: Eli Lilly and Company rose after the United States — Food and Drug Administration approved its new weight loss pill, Foundayo.
Apr 01, 2026 · 14 articles
International
United States: The United States is a primary party in the conflict and negotiations, aiming to secure safe transit in the Strait of Hormuz, curb Iran's nuclear ambitions, and ensure regional stability. Its approval is crucial for any ceasefire extension or final deal.
Eli Lilly and Company: Eli Lilly and Company>>> advanced after CVS Health>>> announced it would restore coverage for its weight-loss injection, Zepbound, and add its new obesity pill Foundayo.
May 18, 2026 · 309 articles
International
United States: The United States is a key negotiator in the ceasefire extension and nuclear talks with Iran, aiming to reopen the Strait of Hormuz and address Iran's nuclear program. The US has also conducted military strikes and imposed sanctions on Iran.
Eli Lilly and Company: Eli Lilly and Company>>> advanced after CVS Health>>> announced it would restore coverage for its weight-loss injection, Zepbound, and add its new obesity pill Foundayo.
May 27, 2026 · 101 articles
Business
United States: The U.S. is a key market for GLP-1 drugs. The study's implications for presenteeism and productivity are relevant but require further validation.
Eli Lilly and Company: Eli Lilly manufactures Mounjaro and Zepbound, GLP-1 drugs included in the study. The findings could enhance the perceived economic value of its products.
Jul 21, 2026 · 6 articles
Business
United States: The United States' stance on potential attacks against Iran and its inventory drawdown affected oil prices. United States — Federal Reserve minutes also indicated concerns about inflation and potential interest rate hikes.
Eli Lilly and Company: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.
May 20, 2026 · 72 articles
Business
United States: The event reflects U.S. healthcare and employment trends, with GLP-1 drugs becoming a significant cost factor for employers. It highlights the national debate over obesity treatment coverage and its economic implications.
Eli Lilly and Company: Eli Lilly is another major GLP-1 manufacturer (Zepbound) and has introduced employer-focused programs to expand coverage. The bank's spending and industry trends benefit Lilly's market position.
Aug 05, 2026 · 6 articles
Tech
United States: Origin of the study and a major market for Tirzepatide.
Eli Lilly and Company: Manufacturer of Tirzepatide; reported strong sales growth and benefits from positive study results.
Aug 05, 2026 · 13 articles
Domestic
United States: The United States is the primary focus of RaiseMe's efforts, as the nonprofit seeks to mitigate potential catastrophic job losses and economic destabilization within the country due to the rapid advancement of artificial intelligence.
Eli Lilly and Company: Eli Lilly is an employer involved in the RaiseMe project, contributing to the nonprofit's goal of adapting the workforce to an AI economy.
Jun 25, 2026 · 7 articles
Domestic
United States: The United States economy faces uncertainty due to new tariffs, with potential for higher inflation, dampened hiring, and increased costs for consumers and businesses.
Eli Lilly and Company: Eli Lilly and Company, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Tech
United States: The studies discussed involve patients and practices within the United States>>> and address a significant health concern for American women.
Eli Lilly and Company: Eli Lilly and Company>>> produces GLP-1 drugs like Zepbound, Mounjaro, and Trulicity, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
Tech
United States: Country where the study was conducted and where GLP-1 use is widespread.
Eli Lilly and Company: Manufacturer of tirzepatide (Mounjaro, Zepbound); similar impact as Novo Nordisk.
Jul 14, 2026 · 6 articles
Tech
United States: Country where the studies were conducted and where insurance coverage and regulatory approval decisions affect patient access to GLP-1 drugs for PMOS.
Eli Lilly and Company: Manufacturer of exenatide, another GLP-1 drug studied for PMOS; potential new indication could boost sales.
Aug 15, 2026 · 12 articles
Domestic
United States: The United States>>> is the primary beneficiary of the TrumpRx program, with its citizens expected to save billions on prescription drug costs due to the 'most favored nation' policy and tariffs.
Eli Lilly and Company: Eli Lilly and Company>>> is one of the pharmaceutical companies participating in the TrumpRx program, agreeing to reduce prices on certain medications.
Jun 06, 2026 · 8 articles
Business
United States: Expanded airstrike campaign against Iran; tensions escalate.
Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.
Apr 20, 2026 · 344 articles
Business
United States: The United States is the focus of BMS's $40 billion investment plan, which includes this United States — Houston campus. The investment supports domestic manufacturing and innovation, aligning with broader national goals.
Eli Lilly and Company: Eli Lilly is mentioned as another pharmaceutical company investing in the same Generation Park area, with a $6.5 billion plant. This highlights the region's growing life sciences cluster but is not directly impacted by BMS's announcement.
Aug 10, 2026 · 20 articles
Business
United States: Cipla's North America revenue declined 21% due to loss of exclusivity on lenalidomide and quality issues with lanreotide; the company expects sequential recovery.
Eli Lilly and Company: Cipla markets obesity drug Yurpeak under a licensing agreement with Eli Lilly; Yurpeak became the second-largest GLP-1 brand in India.
Jul 23, 2026 · 6 articles
Business
United States: The United States is the primary market for the therapies and the regulatory environment is influenced by the Trump administration's executive order.
Eli Lilly and Company: Eli Lilly is the acquirer, paying $2.8B upfront for Atai Life Sciences to bolster its neuroscience pipeline and diversify beyond its weight-loss drug franchise. The deal is part of a broader acquisition spree funded by strong commercial performance.
Jul 16, 2026 · 25 articles
International
United States: The US is a key stakeholder, having blockaded Iranian ports and opposed Iranian control. A deal could reduce oil prices and political pressure, but may be seen as a concession.
Eli Lilly and Company: Eli Lilly and Company raised its forecast, boosting healthcare stocks. It is not connected to the event.
Mar 09, 2018 · 316 articles
Tech
United States: The United States>>> is the host nation for the United States — Food and Drug Administration>>>, which granted Fast Track designation to VERVE-102.
Eli Lilly and Company: As the parent company of Verve PCSK9-inhibitor gene therapy>>>, Eli Lilly and Company>>> is a key developer of VERVE-102, a gene-editing therapy that has shown promising results in lowering cholesterol. This breakthrough could significantly impact its future market position in cardiovascular medicine.
May 26, 2026 · 12 articles
Business
United States: Fluid Crystal technology has commercial and regulatory approvals in the United States.
Eli Lilly and Company: Eli Lilly and Company expanded its exclusive global rights to Camurus' Fluid Crystal technology, allowing it to develop and commercialize long-acting cardiometabolic drugs for an additional compound class, which could lead to new revenue streams.
Jun 01, 2026 · 10 articles
Regulatory
United States: The US previously approved Wegovy for MASH in August 2025, setting a precedent for the Indian approval.
Eli Lilly and Company: Eli Lilly competes with Novo Nordisk in India's obesity-drug market with Mounjaro; the approval may intensify competition.
Jul 17, 2026 · 13 articles
Business
United States: The United States is the regulatory and market jurisdiction for the IPO, with the SEC and Nasdaq based there.
Eli Lilly and Company: Eli Lilly has a strategic collaboration with Scribe, which may benefit from Scribe's successful IPO and pipeline progress.
Jul 06, 2026 · 25 articles
Business
United States: The United States is the target market for Grey Matters Health Inc.'s expansion of neuroimaging clinics, addressing a growing demand for Alzheimer's detection and treatment within the country.
Eli Lilly and Company: Eli Lilly and Company developed Kisunla, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
Business
United States: The United States stock market is the primary focus of these events, with major IPOs and economic data influencing its performance.
Eli Lilly and Company: Eli Lilly and Company is mentioned as one of the companies that SpaceX's valuation will surpass, emphasizing the magnitude of SpaceX's market entry.
Mar 09, 2018 · 538 articles
Business
United States: The United States is the location of the United States — Food and Drug Administration, which has previously approved a drug using Hanmi Pharm. Co., Ltd.'s technology.
Eli Lilly and Company: Eli Lilly and Company obtained exclusive worldwide rights (excluding Korea) to develop, manufacture, and commercialize sonefpeglutide, expanding its pipeline in areas like short bowel syndrome and other indications, potentially leading to new revenue streams.
Jun 01, 2026 · 11 articles
Business
United States: The US approved Awiqli earlier in 2026, contributing to its global rollout.
Eli Lilly and Company: Eli Lilly competes with Novo Nordisk in the obesity treatment market, but this launch is focused on diabetes.
Jul 09, 2026 · 21 articles
Business
United States: The U.S. benefits from increased domestic manufacturing capacity for critical drug substances, enhancing supply chain resilience.
Eli Lilly and Company: Eli Lilly is mentioned as the previous owner of the Tippecanoe site, which was acquired in 2010; no direct impact from this investment.
Jul 08, 2026 · 9 articles
Business
United States: The United States is the primary market for Lantheus' products and the regulatory jurisdiction for the deal, with potential antitrust review.
Eli Lilly and Company: Eli Lilly is mentioned as a prior acquirer of Point Biopharma and as a former partner with Lantheus on a PSMA-directed therapeutic that was abandoned after an unfavorable trial.
Aug 03, 2026 · 7 articles
Business
United States: The United States is one of the countries where Leqembi is already approved; the India launch does not directly affect its market.
Eli Lilly and Company: Eli Lilly faces increased competition in India's Alzheimer's market as Eisai launches Leqembi, potentially impacting its Lormalzi uptake.
Aug 03, 2026 · 6 articles
+ 18 more events
View on Dashboard
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.
Open Dashboard